M&A / Deals Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant Pharmaceutical TechnologyVivani's NanoPortal technology delivers medication steadily over long periods of time.Metabolic & GLP-1Read full story pharminent July 8, 2026 (Last updated: July 15, 2026) Pharmaceutical Technology Vivani’s NanoPortal technology delivers medication steadily over long periods of time. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Novartis Pays $1.1B Upfront for Myricx Bio ADC PlatformNext: AstraZeneca bets up to $1.9B in respiratory disease collab with Sino Biopharmaceutical Related Stories M&A / Deals Supernus and Indivior merge to create CNS mega-company with 11 approved drugs pharminent August 3, 2026 M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026
